1. Scrip
  2. >>Business

Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again

Gorsky And Stoffels Go Out On A High

 
• By Eleanor Malone, Brianna Molnar, and Kosh Naran

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

2022 Titans of Phrama
How much did the leaders of the top 20 pharma companies get paid last year? • Source: Shutterstock

Every year, Scrip and In Vivo’s Titans Of Pharma infographic spotlights the executive compensation packages at big pharma, lining CEO and R&D chief remuneration up against other company metrics including sales, net profits, market cap and median employee compensation. We’ve changed the format this year from a static chart to an interactive dashboard and series of visual graphics that enable readers to explore the numbers across multiple years and data points.

The compensation figures provided in our data charts include base salary, bonus and long-term incentives (including equity awards) and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Gilead Joins Pharma’s US Investment Rush

 
• By Alaric DeArment

The company drew praise from the Trump administration as one of multiple companies announcing multibillion-dollar investments in US manufacturing and R&D.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

More from Scrip

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’